Artiva director Elaine Sorg files Form 3

Artiva Biotherapeutics, Inc. filed an initial insider ownership report for director Elaine K. Sorg on Form 3.

Accepted by SEC EDGAR 02/19/2026 - 09:41 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. filed an initial insider ownership report for director Elaine K. Sorg on Form 3. The filing lists her status as a director and does not report any insider transactions or share purchases or sales at this time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Artiva Biotherapeutics (ARTV) Form 3 for Elaine K. Sorg show?

The Form 3 shows Elaine K. Sorg as a director of Artiva Biotherapeutics, Inc.. It is an initial insider ownership report and, in this case, does not list any insider share transactions or changes in holdings.

Did Elaine K. Sorg buy or sell Artiva Biotherapeutics (ARTV) shares in this Form 3?

No insider trades are reported in this Form 3 for Elaine K. Sorg. The filing indicates zero buy, sell, acquire, or dispose transactions, making it purely an initial registration of her status as a director.

What insider role does Elaine K. Sorg have at Artiva Biotherapeutics (ARTV)?

Elaine K. Sorg is listed as a director of Artiva Biotherapeutics, Inc. in the Form 3. She is not reported as an officer or a ten percent owner in this insider filing data.

Does the Artiva Biotherapeutics (ARTV) Form 3 indicate large ownership or control by Elaine K. Sorg?

The Form 3 does not classify Elaine K. Sorg as a ten percent owner. It only identifies her as a director, and the summarized insider data shows no reported buy, sell, acquire, or dispose transactions in this filing.

Why is there a Form 3 filing for Artiva Biotherapeutics (ARTV) director Elaine K. Sorg?

A Form 3 is required when someone becomes an insider, such as a director. For Elaine K. Sorg, this filing formally records her insider status at Artiva Biotherapeutics, Inc. without reporting any share transactions in this dataset.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sorg Elaine K.

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/18/2026

3. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Andrew Cronauer, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.